Clinical Trials Sponsored by Nanjing Legend Biotech Co.

Total 49 results

Peking University
Nanjing Legend Biotech Co.

Recruiting

A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC)

Advanced Gastrointestinal Tumors

China
Shanghai East Hospital
Nanjing Legend Biotech Co.

Terminated

A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors

Solid Tumors, Adult

China
Beijing Boren Hospital
Nanjing Legend Biotech Co.

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

T-cell Leukemia | T Cell Lymphoma

China
Nanjing Legend Biotech Co.
Janssen Research & Development, LLC

Recruiting

A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (CARTIFAN-1)

Multiple Myeloma

China
Weijun Fu
Nanjing Legend Biotech Co.

Recruiting

BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Weijun Fu
Nanjing Legend Biotech Co.

Active, not recruiting

A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotech Co.

Recruiting

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

China
First Affiliated Hospital Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma

Gastric Cancer | Pancreatic Ductal Adenocarcinoma

China
Institute of Hematology & Blood Diseases Hospital
Nanjing Legend Biotech Co.

Recruiting

A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Unknown

CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Institute of Hematology & Blood Diseases Hospital...
Nanjing Legend Biotech Co.

Terminated

CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Not yet recruiting

Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Lymphoma, B-Cell

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Withdrawn

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Refractory B Acute Lymphoblastic Leukemia | Relapse B Acute Lymphoblastic Leukemia

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia

Acute Myeloid Leukemia | Acute Leukemia | Acute Leukemia in Relapse | Relapsed or Refractory Acute Leukemia

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Unknown

LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

China
Qiu Lugui
Nanjing Legend Biotech Co.

Recruiting

Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
Nanjing Immunophage Biotech Co., Ltd

Not yet recruiting

Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients

Solid Tumor

China
Nanjing Immunophage Biotech Co., Ltd

Recruiting

IPG7236 in Patients With Advanced Solid Tumors

Pharmacokinetics | Safety Issues | Tolerability

United States
Nanjing RegeneCore Biotech Co., Ltd.

Recruiting

A Phase I Study of RC1416 Injection

Healthy Volunteers

China
Nanjing Immunophage Biotech Co., Ltd

Recruiting

Study of IPG1094 in Healthy Participants

Safety Issues

Australia
Shanghai East Hospital
Anhui Provincial Hospital; Nanjing Legend Biotech Co.; East Clinical Center of...

Terminated

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer

Epithelial Ovarian Cancer

China
Jun Zhu
Nanjing Legend Biotech Co.

Recruiting

Collection of PBMCs From Healthy Subjects for the Development of Cellular Immunotherapy Product

Healthy Subject

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co.,Ltd.

Terminated

A Study on the Collection of Peripheral Blood Mononuclear Cells From Healthy Volunteers for the Development of Allogeneic Cellular Immunotherapy Products

Collection of Peripheral Blood Mononuclear Cells by Means of Apheresis

China
Nanjing Immunophage Biotech Co., Ltd
Zhejiang Hospital

Not yet recruiting

Phase 1 Study for IPG11406 in Health Volunteer

Inflammatory Bowel Diseases

China
Changhai Hospital
Nanjing Enricnk Biotech Co., Ltd

Recruiting

The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China
jianming xu
Nanjing Legend Biotech Co.

Recruiting

GPC3-targeting LCAR-H93T Cell in Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Henan Cancer Hospital
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies

Hematologic Malignancies

China
Nanjing Legend Biotech Co.
Ruijin Hospital; Second Affiliated Hospital of Xi'an Jiaotong University; Shanghai... and other collaborators

Active, not recruiting

LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)

Refractory or Relapsed Multiple Myeloma
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL

Neoplasms | Neoplasms by Site | Hematologic Diseases | Hematologic Neoplasms

China
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia

China
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Unknown

Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor Immunotherapy Study

Peripheral Blood Mononuclear Cell

China
Nanjing Immunophage Biotech Co., Ltd
Novotech (Australia) Pty Limited

Not yet recruiting

A Study of Orally Administered IPG7236 in Healthy Adult Participants

Atopic Dermatitis

Australia
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
He Huang
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Bioheng Biotech Co., Ltd.

Unknown

CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Bioheng Biotech Co., Ltd.

Unknown

PBMC Donation in UCAR-T Cells

Peripheral Blood Mononuclear Cell Donation

China
Xiaoyu Zhu
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL

Neoplasms | Hematologic Diseases | Hematologic Neoplasms

China
Biotech Pharmaceutical Co., Ltd.
Fudan University; NanJing PLA 81 Hospital

Completed

A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

Pancreatic Cancer

China
Yi Miao
Nanjing Abingen Biotech Co. Ltd

Unknown

T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System

Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Bowel Cancer | Liver Cancer | Gallbladder Cancer

China
MEI HENG
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies

Neoplasms | Neoplasms by Site | Hematologic Diseases | Hematologic Neoplasms

China
Weijia Fang, MD
Nanjing Blue Shield Biotech Co.,Ltd

Completed

Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer

Ovarian Cancer

China
Kai Lin Xu，MD
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)

Neoplasms | Hematologic Diseases | Hematologic Neoplasms

China
Kai Lin Xu; Jun Nian Zheng
Nanjing Bioheng Biotech Co., Ltd.

Unknown

CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co.,Ltd.; The First Affiliated Hospital of USTC...

Terminated

Study of LUCAR-20S in Patients With R/R NHL

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

China
Guangdong Ruishun Biotech Co., Ltd
Changhai Hospital; Peking University People's Hospital; RenJi Hospital; The Affiliated...

Not yet recruiting

A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotechnology Co. The First Affiliated Hospital of USTC west...

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma

CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

China
920th Hospital of Joint Logistics Support Force...
Nanjing Bioheng Biotech Co., Ltd.

Withdrawn

UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

B-cell Lymphoma

China
Shanghai Jiao Tong University School of Medicine
Guangzhou Psychiatric Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Recruiting

Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)

Clinical High Risk Syndrome of Psychosis

China

Clinical Trials Sponsored by Nanjing Legend Biotech Co.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations